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ABSTRACT
Background: Drug-induced hypersensitivity syndrome (DIHS) is a rare but severe disorder due to a systemic
hypersensitivity reaction. We report on a case with DIHS-like symptoms following human herpes virus 6 (HHV-
6) infection complicated with encephalopathy.
Case Summary: An 11-month-old girl suffered from a human herpes virus 6 (HHV-6) infection (exanthema
subitum) complicated with encephalopathy. We treated the patient with continuous infusion of thiopental, as-
sisted mechanical ventilation, methylprednisolone pulse therapy, and γ-globulin infusion therapy starting on the
fifth day of the illness and started phenobarbital administration on the eleventh day. The patient developed a fe-
ver, systemic erythematous exanthema, lymphadenopathy, and eosinophilia two weeks after the start of phe-
nobarbital administration. Steroid therapy, methylprednisolone (4 mgkgday) followed by oral prednisolone (1
mgkgday), was started on the 28th day and was tapered off on the 72nd day after admission. Serum anti-
HHV-6 IgG antibody elevation and the presence of HHV-6 DNA in the peripheral blood detected by polymerase
chain reaction (PCR) analysis suggested reactivation of HHV-6 after the primary infection of HHV-6. Lympho-
cyte transformation test for phenobarbital was positive three weeks after the DIHS crisis.
Discussion: HHV-6 reactivation is a unique feature in DIHS. In general one develops DIHS accompanied by
reactivation of HHV-6 which has been residing in the body since the initial infection (exanthema subitum) in
early childhood. This is the first report of a patient with DIHS-like symptoms which developed immediately fol-
lowing the primary infection of HHV-6.
KEY WORDS
drug-induced hypersensitivity syndrome, drug-induced lymphocyte transformation test, HHV-6 encephalopa-
thy, hypersensitivity syndrome, phenobarbital
INTRODUCTION
Drug-induced hypersensitivity syndrome (DIHS) is
one of the severe drug eruptions combined with multi
organ disorders.1,2 This syndrome has several unique
features; delayed onset, worsening of clinical symp-
toms even after withdrawal of the causative drugs and
cross-reactivity to multiple drugs with different struc-
tures. A close relationship between reactivation of
herpes viruses including human herpes virus 6
(HHV-6) and the development of DIHS has been sug-
gested.1,3,4
We present an 11-month-old girl who suffered from
DIHS following a primary HHV-6 infection compli-
cated with encephalopathy. DIHS developed 27 days
after the onset of exanthema subitum and 14 days af-
ter the start of phenobarbital treatment.
CLINICAL SUMMARY
The patient was an 11-month-old girl who visited our
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Fig. 1 Clinical course. Solid line indicates HHV-6 antibody in serum, broken line indicates HHV-6 DNA in se-
rum and bold-broken line indicates HHV-6 DNA in CSF. Abbreviations: mPSL, methylpredonisolone; PSL, pre-
donisolone; HHV-6, human herpes virus 6; CSF, cerebrospinal fluid; ICU, intensive care unit; CBZ, 
carbamazepine: PB, phenobarbital; PCR, polymerase chain reaction assay; AST, aspartate aminotransferase; 
ALT, alanine aminotransferase; LD, lactate dehydrogenase; CRP, C-reactive protein; WBC, white blood cel.
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hospital due to right tonic hemiconvulsions and up-
ward deviation of the eyes without any preceding
symptoms. The convulsions were controlled by the
intravenous administration of diazepam one hour af-
ter onset. On admission her body temperature was
39.1℃, heart rate was 148minute and respiration
rate was 30minute. She was ill tempered but her
consciousness was clear. Physical findings were as
follows: skin was free of eruption, throat was injected,
breath sounds were normal, heart sounds were clear
without murmurs, abdomen was soft and flat and
both right upper and lower extremities were para-
lysed. Laboratory data on admission were as follows
(Fig. 1); WBC 14,400μl (eosinophil 0.1%), AST 43
IUl, LD 279 IUl, CRP 0.36 mgdl, BS 145 mgdl.
Head CT revealed no remarkable changes. Rapid in-
fluenza antigen test was negative.
On the forth day of the illness she became afebrile
with normal laboratory data and a milliary sized
erythematous rash appeared over her whole body
which persisted for 3 days. We diagnosed her as suf-
fering from exanthema subitum complicated with feb-
rile seizure. On the fifth day she had a generalized
cluster of right hemiconvulsions. Lumber puncture
showed no abnormal findings but diffusion-weighted
magnetic resonance imaging (DW-MRI) showed ab-
normal hyperintensity in the subcortical white matter
of the frontal lobes.
We treated the patient with continuous infusion of
thiopental and assisted mechanical ventilation. There-
after the seizures were not seen. Intravenous methyl-
predonisolone pulse therapy (30 mgkgday for 3
days), γ-globulin and acyclovir therapy were intro-
duced from the same day. On the tenth day the thio-
pental infusion therapy was discontinued and oral car-
bamazepine was started instead. On the eleventh day
a maculopapular erythematous rash appeared on
face, extremities and trunk. So we changed car-
bamazepine to phenobarbital suspecting a hypersen-
sitivity reaction to carbamazepine. On the 14th day in-
travenous phenytoin injection was added. Afterwards
the erythema subsided with no seizure episodes. We
started nasogastric tube feeding and rehabilitation on
the 17th day. Phenytoin injection therapy was discon-
tinued on the 25th day. At that time she could neither
recognize her parents, nor sit by herself. Right hemi-
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paresis persisted.
On the 27th day the patient had a fever with
erythema over the whole body with cervical lympha-
denopathy. The next day we stopped phenobarbital
therapy suspecting drug allergy. However, the high
fever and erythema continued and facial edema devel-
oped. On the 30th day eosinophil count elevated to
1,927μl. Aspartate aminotransferase (AST) was 105
IUl and alanine aminotransferase (ALT) was 45 IUl.
We suspected DIHS and metylpredonisolone was ad-
ministered intravenously. On the 31st day she be-
came afebrile and skin eruptions disappeared. On the
34th day intravenous metylpredonisolone was
changed to oral predonisolone. On the 35th day she
smiled and could eat orally. Then the erythematous
rash had turned to pigmentation and desquamation.
Gradually she had improved to recognize and look
around at her parents by the 50th day but right hemi-
paresis remained. The EEG showed spikes in the left
temporal lobe and MRI showed slight brain atrophy
on the day of discharge. She was discharged on the
61st day. Subsequently the steroid was tapered off on
the 72nd day. Afterwards no symptoms reappeared.
Her development was as follows: she stood by herself
at 18 months, walked by herself at 19 months and rec-
ognized words at 24 months.
VIROLOGICAL AND SEROLOGICAL STUDIES
HHV-6 DNA was detected in serum (635 copyml)
and CSF (31.5 copyml) on the fifth day of the illness
when she had cluster convulsions during the eruptive
stage of exanthema subitum but was not detected on
the 16th day. It was detected again in the serum on
the 28th day (805 copyml) when she had high fever
and generalized erythema. On the 30th day, serum
HHV-6 DNA was 4360 copyml and DIHS due to
HHV-6 reactivation was suspected. The anti-HHV-6
IgG antibody was negative on the day of admission,
and it was x256 on the 11th day and x128 on the 34th
day. The anti-HHV-6 IgM antibody was not measured
in our patients. The IgG antibody titer against
Epstein-Barr virus was 6.7 (<1.0) and the IgM anti-
body was negative on the 30th day.
DRUG-INDUCED LYMPHOCYTE TRANSFORMA-
TION TEST (LTT)
The results of drug-induced lymphocyte transforma-
tion test on the 45th day for phenobarbital, phenytoin
and carbamazepin were 917%, 239% and 105%, respec-
tively.
DISCUSSION
This is the first report of a patient with DIHS-like
symptoms which developed shortly after the primary
infection of HHV-6. This case is consistent with the
diagnostic criteria of DIHS1 such as maculopapular
rash, fever, esinophilia, lymphoadenopathy and HHV-
6 reactivation, but inconsistent with the criteria in
terms of prolonged clinical symptoms after discon-
tinuation of the causative drug and liver dysfunction
(ALT >100 IUl). Earlier introduction of the steroid
might have contributed to the mild liver dysfunction
and lack of prolonged clinical symptoms in our pa-
tient.
Early recognition and immediate discontinuation of
the causative drug is the most important step in the
treatment of this syndrome. Supportive therapy alone
without the use of systemic steroids may lead to a
cure within a few weeks in mild cases. But this syn-
drome may cause infliction of other organ system
such as myocarditis,5 rhabdomyolysis,6 encephalitis,7
pneumonitis and hepatitis.8 Although there have
been no randomized, controlled trials to prove the ef-
ficacy of steroids, many reports showed the rapid
resolution of the symptoms and fair prognosis with
steroid therapy.1,2 In our case steroid therapy started
four days after the development of high fever,
erythema and slight elevation of ALT which were in-
dicative of DIHS.
The causative drugs of DIHS are anti-convulsants
(carbamazepine, phenytoin, phenobarbital and zon-
isamide), antimicrobials, allopurinol and others.1
Considering the result of LTT and the clinical course,
the causative drug in our patient was phenobarbital.
The number of reports of DIHS in children are few.
Patients under 2 years old are especially rare since
the long term use of anti-convulsants are not common
in infants under 2-years of age.2 Fever and rash in
children may be regarded as symptoms of more com-
mon diseases such as bacterial and viral infection.
Prompt recognition and differential diagnosis is es-
sential for the early treatment in these patients to pre-
vent serious complications.
The pathomechanisms in DIHS remains largely un-
known. HHV-6 reactivation is a unique feature in
DIHS and is not observed in other drug eruptions.
Recent studies have demonstrated that other herpes-
viruses such as Epstein-Barr virus (EBV),9 HHV-7,3
or cytomegalovirus (CMV)10 are reactivated in the
course of the disease as well. These herpesviruses
can be reactivated in DIHS in a sequential order.11 Se-
quential reactivation of various herpesviruses could
result in exacerbations and remissions of clinical
symptoms. The cascade of the reactivation events is
usually initiated by EBV or HHV-6 and followed by
HHV-7 and CMV.12 HHV-6 reactivation can be de-
tected around 2 to 3 weeks after onset being coinci-
dent with overshooting increases in serum Ig levels.
Whether the reactivation of herpesviruses has a
causal role of DIHS or DIHS is initiated by an im-
mune reaction to the incriminated drugs which seem
to have a substantial ability to stimulate T cells is con-
troversial. Recently the role of anti-viral T cells has
been noticed.12 It is postulated that certain drugs
which have intrinsic properties to potentially induce
immunosuppression lead to reactivation of herpes vi-
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ruses, and then activation of anti-viral T cells occurs
followed by cross-reaction with drug antigens. As a
consequence DIHS would ensue.
There have been few reports regarding the possi-
ble etiological association of DIHS with other micro-
organisms including mycoplasma,13 parvovirus B19,14
and paramyxovirus.15
HHV-6 is the causative agent of the popular child-
hood infectious disease, exanthema subitum. It has
been recognized that primary infection of HHV-6 can
cause CNS disorders including febrile seizures and
encephalitisencephalopathy.16 HHV-6 reactivation is
a unique feature in DIHS. In general one develops
DIHS accompanied by reactivation of HHV-6 which
has been residing in the body since the initial infec-
tion as exanthema subitum in early childhood. Our
patient is unique in that DIHS-like symptoms devel-
oped immediately following the primary infection of
HHV-6.
The diagnosis of primary HHV-6 infection was
made based on a typical clinical course compatible
with exanthema subitum and the detection of HHV-6
DNA in the serum and CSF during the early stage of
infection (the fifth day of illness). Negative serum
anti-HHV-6 IgG antibody on the first day and elevated
antibody on the 11th day of illness also support the di-
agnosis of primary HHV-6 infection in our patient.
DIHS associated with primary infections may sug-
gest a novel mechanism which is different from DIHS
developing long after the primary infection. Recent in-
vestigations have disclosed various complicated as-
pects of DIHS. Various cytokines, for example IL-6,
TNF-α, were generated in cases of certain infections.
In patients with DIHS, elevations of TNF-α and IL-6
were reported.17 These cytokines may modify the im-
mune mechanisms inducing interplay among herpes
viruses, antiviral immune responses and drug-specific
immune responses. The elucidation of the pathogene-
sis of DIHS requires further studies.
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